UK Biotech buys Swiss Antibodies to accelerate CAR-T Development

15/07/2016 - 3 minutes

Cell Medica is a London-based biotech which develops, manufactures and markets personalised cell immunotherapeutics for infectious disease and cancer. It has therefore just acquired a Swiss antibody manufacturing biotech Delenex, to help its progress into the CAR-T field.

Update 20/07/16: Cell Medica has also just received EMA Orphan Drug Designation for their CMD-003 candidate. This means it can obtain regulatory and financial incentives for developing and marketing CMD-003, along with a ten-year period of marketing exclusivity within the EU after product approval.

Cell Medica DelenexDelenex is based in Schlieren (Switzerland) and manufactures locally and systemically applied antibody therapeutics. Founded in September 2009, it was a spin-off from Zurich’s ESBATech (now a Novartis company).

On the other hand, Cell Medica is working in collaboration with the Baylor College of Medicine in Texas to develop next-generation cellular immunotherapies incorporating chimeric antigen receptors (CAR). 

Roughly this time last year, the company got FDA Orphan Drug Designation for its leading Cancer immunotherapy (CMD-003) under development for Epstein-Barr Virus positive non-Hodgkin lymphomas

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: